If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: FTSE 100 falls at end of tepid week

Fri, 09th Feb 2024 17:02

(Alliance News) - Stock prices in London closed lower on Friday, with the FTSE 100's losing streak extending to three days, as sentiment in Europe remains tetchy despite a largely stellar start to the day in New York.

The divergence between markets in Europe and New York was perhaps typified by the S&P 500 hitting a record high, cementing its status above the 5,000 point threshold.

The greenback ended the week by returning gains, meanwhile, as a government release denoting consumer price index reading revisions offered little to dollar bulls.

The FTSE 100 index closed down 22.90 points, 0.3%, at 7,572.58. The FTSE 250 ended 40.40 points lower, 0.2%, at 19,062.32, and the AIM All-Share lost 3.69 points, 0.5%, at 747.41.

For the week, both the FTSE 100 and FTSE 250 lost 0.6%, while the AIM All-Share gave back 0.9%

The Cboe UK 100 ended down 0.3% at 756.87, the Cboe UK 250 fell 0.5% to 16,463.05, and the Cboe Small Companies lost 0.3% to 14,534.93.

In European equities on Friday, both the CAC 40 in Paris and the DAX 40 in Frankfurt ended down 0.2%.

In New York, the Dow Jones Industrial Average was down 0.13%, while the S&P 500 added 0.3% and the Nasdaq Composite surged 0.9%.

Having very briefly topped the threshold on Thursday, the S&P 500 opened above 5,000 points on Friday.

"While the Nasdaq 100 and S&P 500 are making new record highs, the latter topping the 5,000 mark, European stock indices found it difficult to keep up and have had a slightly negative end to the week. The FTSE 100 in particular suffered a third straight day of losses ahead of next week's UK unemployment, inflation, Q4 GDP and retail sales data," IG analyst Axel Rudolph commented.

The unemployment, inflation and economic growth readings will be closely eyed by the Bank of England, with the next interest rate decision from Threadneedle Street around six weeks away.

The UK inflation data is released on Wednesday, though there is another reading before the BoE's next decision on March 20.

US inflation data for January is released on Tuesday. According to consensus cited by FXStreet, the annual consumer price inflation rate is expected to have cooled to 3.0% in January, from 3.4% in December.

US inflation data from the end of last year saw little in the way of revisions, according to new data published Friday.

The Bureau of Labor Statistics made minimal revisions to last year's inflation data, with consumer prices excluding food and energy items rising at a 3.3% annualised rate in the final three months of 2023, matching the previous reading.

Revisions to the headline figure were also minimal. December's monthly increase was marked down to a 0.2% advance instead of 0.3%, while the reading for November moved up 0.1 percentage point, also to 0.2%.

The dollar fell back after the figures, which were seen as supporting an interest rate cut in May.

Federal Reserve Chair Jerome Powell and his colleagues have said they need to see more evidence that price pressures are sustainably receding before they begin cutting interest rates.

In late January, Powell eroded hopes for a cut in interest rates in March, saying it is not the "most likely case."

The pound was quoted at USD1.2632 late on Friday in London, up compared to USD1.2609 at the equities close on Thursday. The euro stood at USD1.0783, up against USD1.0763. Against the yen, the dollar was trading at JPY149.31, down from JPY149.39.

In London, there was little in the way of major large-cap moves, with Fresnillo closing among the worst FTSE 100 performers. The gold miner ended down 3.4%, tracking bullion prices lower.

"After a barrage of company announcements this week, it's no wonder that markets have paused for breath on Friday. Investors have had so much to take in from a wealth of big names that they're exhausted by the all the numbers," AJ Bell analyst Russ Mould commented.

Gold was quoted at USD2,021.73 an ounce late Friday afternoon, down against USD2,029.31 late Thursday and off the USD2,034.63 it fetched this time last week. Gold traded as low as below the USD2,015 mark earlier this week.

ACY Securities analyst Luca Santos commented: "Gold, the age-old symbol of wealth and stability, has recently faced a significant challenge, breaking below a crucial technical support level at USD2.017 per ounce. This development sends a negative signal for both gold and silver. There is even a possibility of a further slide to the mid USD1.980 per ounce level, indicating a challenging period for gold investors."

Recently the object of takeover interest, packaging firm DS Smith and housebuilder Redrow climbed 2.5% and 0.3%, extending gains. Peer Mondi is mulling a takeover of DS Smith, while Redrow has agreed to a housebuilding tie-up with Barratt Developments.

There was some more dealmaking on Friday.

Barclays is to buy the retail banking business of Tesco Bank, as the big UK supermarkets scale back their forays into financial services.

Tesco said it will sell to Barclays all of its banking operations in credit cards, loans and savings to Barclays, while retaining other activities of Tesco Bank including insurance, automatic teller machines, travel money and gift cards. The supermarket noted that these businesses are capital-light, profitable, and have a strong connect to its core retail offer.

Barclays will pay about GBP600 million for the business, which has been in operation for more than 25 years. Tesco noted it will receive about GBP1 billion in cash in total, including a special dividend of GBP250 million paid by Tesco Bank back in August.

Tesco shares closed marginally higher, while Barclays fell 0.6% in a tricky day for London-listed lenders.

HSBC shares fell 1.3%, weighing on the FTSE 100. NatWest, meanwhile, gave back 2.2%, before it reports annual results next week Friday.

Elsewhere in London, AIM-listed Evgen Pharma slumped 22% as it announced it has issued a notice of dispute with partner Stalicla, explaining that it has not received funds it believes it is entitled to.

"In October 2022, Evgen licensed the global rights for lead asset SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla for up to USD160.5 million in milestone payments. An initial USD500,000 was paid upfront with the next anticipated payment of USD500,000 due on completion of the Evgen-sponsored human volunteer Phase 1 study.

"The phase 1b human volunteer study was completed and the clinical study report finalised in August 2023."

Evgen said it believes the "payment is now due".

"In order to effect the payment, Evgen has taken the decision to formally implement the dispute resolution process detailed in the License Agreement, the first step of which is the issuance of a dispute notice. As stated in the half year results in October 2023, Evgen has not anticipated any milestone payments from Stalicla in its financial forecasting and its cash runway remains unchanged," it added.

Brent oil was quoted at USD82.03 a barrel late in London on Friday, up from USD81.02 late Thursday.

On Monday, financial markets in Shanghai and Tokyo are closed for the Chinese New Year and National Day holidays, respectively.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
27 Jul 2018 13:14

Friday broker round-up

(Sharecast News) - William Hill: Peel Hunt upgrades to hold with a target price of 305p.

Read more
26 Jul 2018 12:54

Evgen Pharma Expects Final Results From Clinical Trials At End Of Year

LONDON (Alliance News) - Evgen Pharma PLC said Thursday it expects to receive the final read-out from two clinical trials by the end of 2018.The drug development company said at its annual

Read more
25 Jul 2018 14:48

Evgen concludes patient recruitment in STEM breast cancer trial

(Sharecast News) - Clinical-stage drug development company Evgen Pharma has concluded patient recruitment in its STEM Phase IIa trial of SFX-01 in metastatic breast cancer, it announced on Wednesday.

Read more
25 Jul 2018 13:57

Wednesday broker round-up

(Sharecast News) - Unite Group: Numis downgrades to hold with a target price of 900p.

Read more
25 Jul 2018 13:31

Evgen Pharma Metastatic Breast Cancer Trial Ends Patient Recruitment

LONDON (Alliance News) - Evgen Pharma PLC said Wednesday it has concluded its patient recruitment for its STEM Phase IIa trial of SFX-01 in metastatic breast cancer.Following the favourable

Read more
19 Jul 2018 16:21

UK Shareholder Meetings Calendar - Next 7 Days

Friday 20 JulyHomeserveKCOM GroupMonday 23 JulyEthernity Energy 24

Read more
13 Jun 2018 10:46

Evgen Pharma Annual Loss Narrows As It Continues Phase II Trials

LONDON (Alliance News) - Clinical drug development company Evgen Pharma PLC said Wednesday its annual loss narrowed in line with expectations.Evgen, which focuses on cancer and neurological

Read more
11 Jun 2018 11:33

Evgen STEM Interim Trial Result Show "Signs Of Anti-Tumour Activity"

LONDON (Alliance News) - Evgen Pharma PLC said Monday its STEM trial showed "early signs of anti-tumour activity" in breast cancer patients.STEM is the company's study of in a

Read more
2 May 2018 11:15

Evgen Pharma Gets European Patent For Sulforaphane Stablising Method

LONDON (Alliance News) - Drug development company Evgen Pharma said Wednesday that it has secured a European patent recognising its intellectual property for a method of stabilising sulforaphane,

Read more
20 Mar 2018 13:56

Evgen Pharma Begins Research Partnership With Imperial College London

LONDON (Alliance News) - Drug development company Evgen Pharma PLC has started a new research collaboration with Imperial College London focusing on SFX-01, the company's

Read more
13 Feb 2017 08:21

Evgen Pharma signs service agreement with drug development corsortium

(ShareCast News) - AIM-listed Evgen Pharma has signed a services agreement with a consortium of Cheshire-based drug developments firms for its sulforaphane product. APT Trans, the consortium of drug developers based in the Biohub at Alderley Park, which comprises of Aptus Clinical, Apconix and Seda

Read more
17 Jan 2017 12:35

Richard Moulson to join Evgen Pharma as CFO

(ShareCast News) - Clinical-stage drug development company Evgen Pharma announced the appointment of experienced healthcare executive Richard Moulson as its chief financial officer on Tuesday. The AIM-traded firm said Moulson was joining immediately as CFO-designate for a handover period to 28 Febru

Read more
11 Jan 2017 09:23

Evgen Pharma receives go ahead for haemorrhage drug trial

(ShareCast News) - Evgen Pharma, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has received a positive interim safety review from the independent Data Safety Monitoring Board (DSMB) for its Phase II double-blind placebo-controlled SAS trial

Read more
11 Jan 2017 09:17

Evgen Pharma Gets Positive Review For SFX-01 Phase II Study

Read more
17 Aug 2016 10:49

Evgen Pharma receives approval for breast cancer study

(ShareCast News) - Clinical stage drug development company Evgen Pharma announced on Wednesday that it has received a Clinical Trial Approval from the UK's regulatory agency for the commencement of its Phase II clinical trial of SFX-01 in breast cancer. The AIM-traded firm said patient recruitment w

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.